• Gianluca Bagnato, Egidio Imbalzano, Carmelo Ioppolo, Daniela La Rosa, Marianna Chiappalone, Alberta De Gaetano, Valeria Viapiana, Natasha Irrera, Veronica Nassisi, Maria Concetta Tringali, Emanuele Balwinder Singh, Nicola Falcomatà, Vincenzo Russo, Neal RobertsWilliamWDepartment of Medicine, University of Kentucky, Lexington, KY 40506, USA., Pierpaolo Di Micco, and Antonio Giovanni Versace.
• Department of Clinical and Experimental Medicine, University of Messina, 98100 Messina, Italy.
• Medicina (Kaunas). 2023 Dec 29; 60 (1).

AbstractBackground and Objectives: In patients with COVID-19, high-flow nasal cannula (HFNC) and continuous positive airway pressure (CPAP) are widely applied as initial treatments for moderate-to-severe acute hypoxemic respiratory failure. The aim of the study was to assess which respiratory supports improve 28-day mortality and to identify a predictive index of treatment response. Materials and Methods: This is a single-center retrospective observational study including 159 consecutive adult patients with COVID-19 and moderate-to-severe hypoxemic acute respiratory failure. Results: A total of 159 patients (82 in the CPAP group and 77 in the HFNC group) were included in the study. Mortality within 28 days was significantly lower with HFNC compared to CPAP (16.8% vs. 50%), while ICU admission and tracheal intubation within 28 days were significantly higher with CPAP compared to HFNC treatment (32% vs. 13%). We identified an index for survival in HFNC by including three variables easily available at admission (LDH, age, and respiratory rate) and the PaO2/FiO2 ratio at 48 h. The index showed high discrimination for survival with an AUC of 0.88, a negative predictive value of 86%, and a positive predictive value of 95%. Conclusions: Treatment with HFNC appears to be associated with greater survival and fewer ICU admission than CPAP. LDH, respiratory rate, age, and PaO2/FiO2 at 48 h were independently associated with survival and an index based on these variables allows for the prediction of treatment success and the assessment of patient allocation to the appropriate intensity of care after 48 h. Further research is warranted to determine effects on other outcomes and to assess the performance of the index in larger cohorts.

14 keywords...

hide…